Furthermore, our data suggest that the combination of KRASG12C inhibitory drugs and COX2 or EP2 to EP4 prostaglandin receptor inhibition may be successful in the treatment of immune hot lung cancer, and it might be speculated that it could possibly avoid the toxicities reported for sotorasib and PDL1 blockade. This evidence concerns the gene CD274 and lung cancer.